An interventional study of platelet rich plasma + Hyaluronic acid and platelet rich plasma + normal saline in Knee Osteoarthritis, sponsored by Tri-Service General Hospital. Completed at 1 site in Taiwan. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-13.
Sponsored by Tri-Service General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing platelet rich plasma in Osteoarthritis, Knee — 3 open to participants now, 4 under way, 1 of them phase 3. platelet rich plasma · Osteoarthritis, Knee.
Among the 43 studies testing platelet rich plasma in Osteoarthritis, Knee, this one is the 29th largest by enrollment, is one of 3 that started in 2018, is one of 14 with no phase, and was the 19th registered.
3,296 studies on the registry are indexed under Osteoarthritis, Knee; 625 are open to participants now.
Browse Osteoarthritis, Knee studies →3 of the 43 studies testing platelet rich plasma in Osteoarthritis, Knee are open now, in 3 countries. Recruiting first, the newest first:
Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz · Sites in Poland
Ages 18–45
Endeavor Health · Sites in United States
Ages 18–75
University Hospital of North Norway · Sites in Norway
Ages 40–70
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 15 · Phase 3 10 · Phase 4 3
First in 2008; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 68 across 2,718 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 60 across the 43 interventional studies. Of the 33 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 43 have an industry lead sponsor. The 10 most frequent:
Tri-Service General Hospital is the lead sponsor of 108 studies on the registry; 11 are open to participants now.
Tri-Service General Hospital has 2 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
1 of the studies testing platelet rich plasma in Osteoarthritis, Knee that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07473232Pamukkale UniversityComparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS) | 2027-01-18 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies testing platelet rich plasma in Osteoarthritis, Knee, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Although platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for osteoarthritis of knee (OA knee), the combined effect of PRP with HA was not clear so far. Hence, investigator assess a prospective randomized double-blind controlled trial.
Patients with single or bilateral OA knee will be enrolled and randomized into intervention and control group. One dose of PRP is applied into both groups. One week later, one dose of HA is injected in intervention group and one dose of normal saline is injected in control group. Outcome measurements included visual analog scale (VAS)、Lequesne's severity index、Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)、balance test (Biodex) and analysis of synovial fluid at different follow-up frame (1st month, 3rd month, 6th month and 1 year after treatment).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee. Patients received one dose of PRP injection. One week later, the one dose of HA is injected for intervention group.
Drug: platelet rich plasma + Hyaluronic acid
Patients received one dose of PRP injection. One week later, the one dose of normal saline is injected for control group.
Drug: platelet rich plasma + normal saline
Drug pages: Platelet rich plasma · Hyaluronic Acid
Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.
The normal salin as the placebo intervention was injection control group.
Change from baseline in severity of symptoms and functional status on 1st month, 3rd month, 6th month and one year after injection.
Using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) to measure the symptoms and functional status before treatment and multiple time frame after treatment. Both subscales has the scores ranged from 1 to 5 for each item and a higher score indicating more severe of symptom or impaired functional status.
Time frame: Pre-treatment, 1st month, 3rd month, 6th month and one year after injection.
Change from baseline in severity of symptoms and functional status on 1st month, 3rd month, 6th month and one year after injection.
Using the Lequesne's severity index to measure the symptoms and functional status before treatment and multiple time frame after treatment. A higher score indicate more severe.
Time frame: Pre-treatment, 1st month, 3rd month, 6th month and one year after injection.
Change from baseline of pain on 1st month, 3rd month, 6th month and one year after injection.
Using the Visual analog scale (VAS) to measure the pain scale before treatment and multiple time frame after treatment. The score ranging from 10 (remarkable pain) to 0 (no pain).
Time frame: Pre-treatment, 1st month, 3rd month, 6th month and one year after injection.
Change from baseline in balance function on 1st month, 3rd month, 6th month and one year after injection.
Using the balance test (Biodex) to measure the balance function before treatment and multiple time frame after treatment.
Time frame: Pre-treatment, 1st month, 3rd month, 6th month and one year after injection.
Change from baseline in analysis of synovial fluid on 6th month and one year after injection.
The synovial fluid is aspirated to measure the parameters before treatment and multiple time frame after treatment.
Time frame: Pre-treatment, 6th month and one year after injection.
Ran from Jan 2018 to primary completion in Jul 2021, 41 months.
Of 1,113 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 41 months is above that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Platelet rich plasma · Hyaluronic Acid
Tri-Service General Hospital →